The potential merits and disadvantages of ionic versus
|
|
- Rosanna Mathews
- 5 years ago
- Views:
Transcription
1 Influence of a Nonionic, Iso-Osmolar Contrast Medium () Versus an Ionic, Low-Osmolar Contrast Medium () on Major Adverse Cardiac Events in Patients Undergoing Percutaneous Transluminal Coronary Angioplasty A Multicenter, Randomized, Double-Blind Study Michel E. Bertrand, MD; Enrique Esplugas, MD; Jan Piessens, MD; Wenche Rasch, PhD; for the Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators Background The potential merits and disadvantages of the use of ionic or nonionic contrast media in patients undergoing percutaneous transluminal coronary angioplasty (PTCA) have been the subjects of controversy. The present study was designed to evaluate the possible influence of both types of contrast media on major adverse cardiac events (MACE) in patients undergoing PTCA. Methods and Results In a randomized, parallel-group, double-blind study, 1411 patients received either iodixanol (a nonionic, iso-osmolar contrast medium) or ioxaglate (an ionic, low-osmolar contrast medium) during PTCA. A standardized anticoagulation regimen was followed. Patients were monitored in the hospital for 2 days and followed-up at 1 month. The primary end point, a composite of MACE (death, stroke, myocardial infarction, coronary artery bypass grafting, and re-ptca) after 2 days, occurred in 4.3% of the total population, with no statistically significant difference between groups (iodixanol, 4.7%; ioxaglate, 3.9%; P 0.45). Further, between 2-day and 1-month follow-ups, no significant difference (P 0.27) existed between the groups in the rates of MACE. Hypersensitivity reactions (P 0.007) and adverse drug reactions (P 0.002) were significantly less frequent in the iodixanol group. The only significant predicting factors for the occurrence of MACE were dissection/abrupt closure and country. Conclusions No significant differences were observed between the iodixanol and ioxaglate groups with regard to MACE, although hypersensitivity and adverse drug reactions were significantly less frequent in patients who received iodixanol. (Circulation. 2000;101: ) Key Words: contrast media angioplasty angiography stents The potential merits and disadvantages of ionic versus nonionic contrast media during percutaneous transluminal coronary angioplasty (PTCA) and the influences of these media on clinical outcome are controversial. 1 8 Thrombosis and vessel dissection may influence the clinical outcome after coronary angioplasty, a procedure that invariably damages the endothelium and produces varying degrees of medial injury. It has been suggested that ionic contrast media may be advantageous in this setting because they can act as anticoagulants and inhibitors of platelet aggregation, whereas nonionic contrast media do not have these effects. 1 8 However, results from preclinical studies are equivocal In addition, clinical data are limited, and no study has shown an increase in major adverse cardiac events (MACE) after the administration of nonionic compared with ionic contrast media. Therefore, we designed a large-scale clinical study to evaluate the possible effects of an ionic (ioxaglate) and a nonionic (iodixanol) contrast medium on clinical outcome and MACE in patients undergoing PTCA. The primary end point was a composite of MACE, defined as death, stroke, myocardial infarction (MI), and the need for coronary artery bypass grafting (CABG) or repeated PTCA (re-ptca). The study population was composed of patients who had stable or unstable angina or silent ischemia. Methods Study Design A multicenter, parallel-group, randomized, double-blind study was conducted in 32 centers in 5 European countries (Belgium, France, Spain, Sweden, and The Netherlands). It was designed to compare the effects of the nonionic, iso-osmolar contrast medium iodixanol 320 mg per I/mL (Visipaque, Nycomed Imaging AS) and the ionic, Received March 17, 1999; revision received July 7, 1999; accepted July 28, From the Division of Cardiology, Lille University Heart Institute, Lille, France (M.E.B.); Hospital de Bellvitge Princeps D Espanya, Barcelona (E.E.); Nycomed Amersham, Oslo, Norway; and Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium (J.P.). Correspondence to M.E. Bertrand, MD, Division of Cardiology, Lille University Heart Institute, Boulevard du Professeur Leclercq, Lille, France. mbertrand@univ-lille2.fr 2000 American Heart Association, Inc. Circulation is available at 131
2 132 Circulation January 18, 2000 low-osmolar contrast medium ioxaglate 320 mg I/mL (Hexabrix, Guerbet SA) in patients undergoing PTCA. Intracoronary stenting was allowed, and it was classified as planned or unplanned. The aim of the study was to assess the influence of the choice of contrast medium and of other clinical and procedural factors (eg, clinical presentation, age, sex, and stenting condition) on the occurrence of MACE after PTCA. Anticoagulation was standardized and monitored during the procedure by repeated measurements of the activated clotting time (ACT). The patients were randomized to receive 1 of the 2 contrast media, which were placed in identical vials to achieve double blinding. The local ethics committees and the national regulatory authorities of each institution and country approved the protocol. Informed written consent was obtained from each patient before enrollment in the trial. Patients Between November 21, 1996, and September 22, 1997, 1541 patients 18 years of age who had stable (Canadian Cardiovascular Society functional classification) or unstable angina (Braunwald s classification system) or silent ischemia and who were undergoing PTCA were enrolled in the study. Exclusion criteria were recent ( 7 days) acute MI, unprotected left main stenosis, or the need for oral anticoagulation with antivitamin K. Patients were also excluded if they had contraindications to heparin, aspirin, or ticlopidine therapy or to iodinated contrast media. Patients who had received iodinated contrast media within the 18 hours before PTCA were not included to minimize the possible influence of nonstudy contrast media on the results. The use of rotablator, directional atherectomy, or pretreatment with glycoprotein IIb/IIIa receptor inhibitors was not allowed. Left ventricular ejection fraction was required to be 35%. In a few centers, recruitment of patients was performed before diagnostic catheterization, and trial contrast medium was then used for that purpose to ensure identical contrast media throughout the procedures. Among the 1541 patients enrolled, 81 did not have PTCA, 27 had major protocol violations (the majority due to an ejection fraction 35% or to the presence of a recent MI), 26 were excluded because they received a mixture of different contrast media, 3 were excluded due to loss of their case report form or contrast medium vials, and 7 were excluded for 1 of the above-mentioned reasons. Of the 1411 patients who constituted the per-protocol population, 697 received iodixanol and 714 received ioxaglate. All patients received heparin, and all but 4 received an antiplatelet agent ( 100 mg of aspirin and/or ticlopidine). An intravenous bolus of heparin ( IU) was administered at the start of the procedure. The ACT was measured 5 minutes after the first injection of heparin, and further heparin was given if necessary to maintain the ACT above 250 or 300 s (depending on the apparatus used). If PTCA lasted 1 hour, ACT was recorded again, and additional heparin was given when required. ACT was measured again at the end of the procedure. Ticlopidine was given to patients after stent implantation or if otherwise indicated (eg, allergy to aspirin). Overall, 68.6% of patients received ticlopidine either before, as routine medication, or before/during/after PTCA. All other medications and procedures were at the discretion of the investigator. Follow-Up Procedural and safety outcomes were recorded for all patients during the hospital stay (2-day follow-up). The primary end point was a composite of MACE during the 2-day follow-up period (2-day MACE); it was defined as death, stroke, Q-wave or non-q-wave MI (NQWMI), and CABG and/or emergency re-ptca at the target lesion or in the target vessel. The definition of a NQWMI was an increase in serum creatine kinase (CK) to twice the upper normal reference range limit or more, coupled with an increase in the CK-isoenzyme MB fraction. An independent end point classification committee evaluated CK for all patients to determine NQWMI cases. This independent end point classification committee, which consisted of 3 cardiologists, also evaluated, in a blinded fashion, all reported MACE-2 day cases. The committee s decision was based on information from the case report form, ECGs, vital signs, laboratory test results (pre- and post-ptca), and films/videos from the PTCA TABLE 1. Baseline Clinical Characteristics (Nonionic; n 697) (Ionic; n 714) Age, y Male, % Weight, kg Height, cm Diabetes, % Current smokers, % Former smokers, % Obesity, % Family history of CAD, % Prior MI, % Prior PTCA, % Prior CABG, % History of allergy/hypersensitivity, % Indication for PTCA*, % Unstable angina Stable angina Silent ischemia Data are mean SD unless otherwise indicated. CAD indicates coronary artery disease. *0.4% were reported as unknown. procedure. In addition to the in-hospital follow-up, the patients were contacted by telephone (by the investigator or a study nurse) 1 month after discharge from the hospital to ascertain if they had been rehospitalized due to MACE. The end point classification committee did not evaluate occurrence of MACE between the 2-day and 1-month follow-ups. Statistical Analysis To assess the influence of contrast media and other factors on the occurrence of 2-day MACE, the factors were individually evaluated through odds ratio (OR) estimates and their associated 95% confidence intervals (single-factor analyses). Testing OR deviations from 1 was done through the 2-tailed likelihood 2 test; P 0.05 was considered statistically significant. In addition, an exploratory multiple logistic regression analysis was performed based on the results of the single-factor analysis to identify the predictors for 2-day MACE; it took into account possible interactions between factors. Other adverse events, including hypersensitivity reactions, were compared between contrast media groups at 2 days and at 1 month using the 2 test. The comparability of the 2 contrast media groups with regard to baseline characteristics was assessed through the dependency of the primary end point on each baseline characteristic. For each baseline characteristic, the 2 P value for testing independence between the baseline characteristic and primary end point was calculated per contrast medium group; P 0.05 indicates dependency. In cases where dependency is found, a large difference in the baseline characteristics between the contrast media groups might then have unwanted effects on the comparability of the groups. Results Baseline Characteristics The baseline clinical characteristics of the study population are presented in Table 1 and were similar in both contrast media groups. The indications for PTCA and the location of the treated lesions did not differ between the groups. Baseline angiographic characteristics are given in Table 2. No signif-
3 Bertrand et al vs for Cardiac Events 133 TABLE 2. Baseline Angiographic Characteristics and Procedural Outcomes (Nonionic; n 697) (Ionic; n 714) Primary lesion location, % LAD RCA Cx Stenosis, primary lesion, %* Baseline Post-PTCA Thrombus, all lesions, % Baseline Post-PTCA Abrupt closure, all lesions, % Dissection, all lesions, % Intracoronary stent, total, % Planned Not planned Planned and not planned Total contrast dose, ml Data are mean SD unless otherwise indicated. LAD indicates left anterior descending coronary artery; RCA, right coronary artery; and Cx, circumflex coronary artery. *Mainly based on visual assessment. Both planned and unplanned stent(s) were implanted. icant relationships existed between the baseline characteristics listed in Tables 1 and 2 and 2-day MACE. Specifically, for presence of diabetes and family history of coronary artery disease, the 2 factors for which frequencies between the contrast medium groups deviated most, the probability values for testing of independence were all Hence, these random deviations had no influence on the rate of 2-day MACE in the contrast media groups. The majority of the patients underwent single-vessel PTCA (73.0% versus 71.1%, iodixanol group versus ioxaglate group). A total of 23% of the patients (22.2% in the iodixanol group versus 23.4% in the ioxaglate group) had 2-vessel PTCA, whereas the remaining patients underwent 3-vessel PTCA. Glycoprotein IIb/IIIa receptor inhibitors were given during or after the PTCA procedure in 23 patients (12 iodixanol and 11 ioxaglate) who had abrupt closure, stent occlusion, or coronary dissection. Procedural Outcome The percent diameter stenosis at baseline and after PTCA are reported in Table 2. No difference in percent residual stenosis existed between the 2 groups immediately after PTCA. The proportion of angiographically identifiable thrombus (visual assessment) before and after PTCA was similar in both contrast media groups (all lesions included) (Table 2). The rates of abrupt closure (all lesions) occurring during the procedure did not differ significantly between groups (P 0.39). Procedure-related dissections were reported somewhat less frequently in patients allocated to the iodixanol group compared with the ioxaglate group, but the difference TABLE 3. MACE at 2-Day Follow-Up (Nonionic; n 697) (Ionic; n 714) During hospital stay (2 days) 33 (4.7%) 28 (3.9%) 0.45 Death 0 2 NS Stroke 2 1 NS Q-wave MI 3 3 NS NQWMI CABG 1 1 NS Re-PTCA 3 4 NS was not statistically significant (P 0.18) (Table 2). Implantation of intracoronary stents was similar in both groups: 59.8% in the iodixanol group and 60.9% in the ioxaglate group. The implantation rate varied from 36.0% in the country with the lowest stent implantation rate (France) to 76.9% in the country with the highest rate (Belgium). Primary End Point On the basis of the intention-to-treat population (1538 patients, 765 in iodixanol group and 773 in ioxaglate group), which consisted of all enrolled patients but the 3 who had a lost case report form or contrast medium vials, the primary end point (2-day MACE) occurred in 4.2%, with no statistically significant differences between the iodixanol and the ioxaglate groups (4.6% versus 3.8%, respectively; P 0.42). Among the MACE, NQWMI was the most frequent complication (2.7%). The analysis of the per-protocol population (1411 patients) showed similar results (Table 3). No statistically significant differences existed between the iodixanol and the ioxaglate groups (4.7% versus 3.9%; P 0.45). Among the 2-day MACE, NQWMI was the most frequent complication (2.9%). The majority (76%) of these patients had a 4-fold increase in CK values. Two cardiac deaths occurred during the 2-day follow-up period, both in the ioxaglate group. The 2-day MACE rate varied among the centers, from 0% to 18.2% among those completing their inclusion. One center enrolled only 7 patients and reported 2 patients with 2-day MACE. Patients who underwent stent implantation had a 4.6% chance of developing 2-day MACE; the chance was 3.3% when stenting was planned and 5.3% when it was unplanned. The rate for nonstented patients was 3.9%. Table 4 shows the ORs with 95% confidence intervals for potential predictive factors of the occurrence of 2-day MACE. Results from the single-factor analyses showed that only dissection/abrupt closure (P 0.001) and country (P 0.005) were significant predictors of the occurrence of 2-day MACE. The presence of the most severe kind of lesion, type C, was borderline with respect to its significance as a predictor (P 0.06). As shown in Table 4, contrast medium, sex, age, clinical condition of the patient, and stenting condition were not significant predictors for the occurrence of 2-day MACE. The multifactorial analysis gave similar results. One-Month Follow-Up Similarly, in the per-protocol population, no statistically significant differences between the 2 groups were observed P
4 134 Circulation January 18, 2000 TABLE 4. ORs, Confidence Intervals, and P Values TABLE 5. Adverse Events in Patients OR 95% Confidence Interval P Dissection or AC Country* Spain Belgium The Netherlands Sweden France Type C lesion Unplanned stent Female Planned stent Clinical condition Silent ischemia Stable angina Unstable angina Age, y Contrast medium, iodixanol AC indicates abrupt closure. *Other countries are compared with France. Clinical conditions are compared with unstable angina. Ages are compared with age 70. is compared with ioxaglate. (P 0.27) with regard to rehospitalization due to MACE during the period between the 2-day and 1-month follow-up. The number of patients hospitalized for each event in each group (iodixanol/ioxaglate) are as follows: cardiac death (2/0), stroke (1/0), Q-wave MI (2/0), NQWMI (1/1), CABG (2/1), and Re-PTCA (6/7). In total, 23 patients (1.6%) were rehospitalized during this time period, 2.0% in the iodixanol group and 1.3% in the ioxaglate group. These events were not validated by the end point classification committee. Combining MACE noted at 2-day follow-up and those occurring between the 2-day to 1-month follow-ups showed no statistically significant difference between the iodixanol and ioxaglate groups (6.3% versus 5.2%; P 0.42). Adverse Events The percentage of patients reporting 1 adverse event during the 2-day follow-up, including MACE, was similar in the 2 groups (27.5% versus 27.6%; Table 5). Chest pain was the most common event reported; this was followed by hypotension, hematoma at the puncture site, nausea or vomiting, and bradycardia. As seen in Table 5, patients randomized to the ioxaglate group had an increased risk (P 0.002) of experiencing adverse events that were classified by the investigators as having a certain relationship to the contrast medium. These were mainly nausea, vomiting, and rash. When pooling contrast media related adverse events and events having an uncertain relationship to contrast media, the overall adverse (Nonionic; n 697) (Ionic; n 714) Adverse events 192 (27.5%) 197 (27.6%) 0.98 Total no. of adverse events Adverse drug reactions 69 (9.9%) 85 (11.9%) 0.23 CM-related, certain 7 (1.0%) 25 (3.5%) CM-related, uncertain 62 (8.9%) 60 (8.4%) Hypersensitivity reactions 5 (0.7%) 18 (2.5%) Types of hypersensitivity reactions Anaphylactic shock 0 1 Rash/urticaria/pruritus 5 12 Coughing/throat tightness 0 2 Rigor* 0 1 Fever 0 1 Vomiting* 0 1 Flushing 0 1 Data are no. of patients unless otherwise indicated. CM indicates contrast medium. *Same patient. drug reaction frequencies were 9.9% in the iodixanol group and 11.9% in the ioxaglate group (P 0.23). Among the most common adverse drug reactions with an uncertain relationship to contrast medium were hypotension, bradycardia, chest pain, and hematoma. Patients randomized to receive the ionic contrast medium ioxaglate had an increased risk of developing hypersensitivity reactions (P 0.007) (Table 5). A total of 23 patients had such reactions, 5 (0.7%) in the iodixanol group and 18 (2.5%) in the ioxaglate group. Discussion Although nonionic contrast media are better tolerated than ionic contrast media, their potential merits and disadvantages in patients undergoing interventional procedures have been a controversial subject. 1 7 Studies in vitro have demonstrated differences in vascular biocompatibility between the isoosmolar nonionic contrast medium iodixanol and the ionic contrast medium ioxaglate Although both contrast media display anticoagulant and antiplatelet properties in this setting, such effects are more marked with ioxaglate. 19,20 However, iodixanol is the most biocompatible, particularly with regard to cultured endothelium 21 and vascular smooth muscle. 22 Data on collagen- or tissue factor induced arterial thrombus formation in native blood and blood including clinically relevant doses of aspirin and heparin were recently published. 23,24 They demonstrate no significant effects of iodixanol, ioxaglate, or the nonionic contrast medium iohexol on thrombin-driven (tissue factor) or platelet-driven (collagen) thrombus formation. Previously published clinical studies on intravascular thrombotic events and outcomes were limited, and the patient populations studied were relatively small at the time the trials were conducted. A recent exception is the study reported by Schräder et al. 25 Therefore, it was P
5 Bertrand et al vs for Cardiac Events 135 necessary to perform a large-scale, blinded, well-controlled study, with objective hard end points. The major finding of this multicenter study was that no difference was found in MACE between the nonionic isoosmolar and the ionic low-osmolar contrast media after both 2 days and 1 month. These results agree with the recently reported single-center trial performed by Schräder et al. 25 In this randomized study comparing the nonionic iomeprol (Iomeron, Bracco-Byk-Gulden) to the ionic ioxaglate in a large series of 2000 patients, no differences were found with regard to angiographic or clinical end points. Fewer than 20% of their patients had unstable angina, and glycoprotein IIb/IIIa receptor inhibitors were not used. However, the present study s results differ from those reported in a single-center study by Grines et al. 4 They compared ioxaglate and the low-osmolar, nonionic contrast medium iohexol (Omnipaque, Nycomed Imaging AS) in 211 patients with acute MI and unstable angina undergoing PTCA. Their conclusion was that the use of the ionic contrast medium ioxaglate reduced the risk of ischemic complications, both acutely and at 1-month follow-up. Results from recently published studies on the effects of iohexol, iodixanol, and ioxaglate on vessel-wall biocompatibility and on arterial thrombus formation 23,24 do not support the findings of Grines et al. 4 However, it is difficult to directly compare the results from the present study with those from Grines et al, 4 because many essential differences exist between the studies. We think that the main reasons for discrepancies in results are that the present study included a much larger patient population (it was a multicenter study, with 7 times as many patients), patients with acute MI were excluded, adjuvant anticoagulation was strictly controlled, and intracoronary stenting was done according to current practice. Finally, the nonionic contrast medium was different in the 2 studies; the present study used the new iso-osmolar iodixanol. With regard to predictive factors for the occurrence of MACE, only the procedure-related factors dissection and abrupt closure were significant, in addition to country (P 0.45 for contrast medium). Regarding the procedural aspects, we noted no difference between the 2 groups in thrombus, abrupt closure, or dissection. However, the identification of thrombus is based on angiographic assessment, and it is well known that angiography has a poor sensitivity for the detection of thrombus. This study reflects the present situation in Western Europe regarding the implantation of intracoronary stents. On average, 60% of the patients were stented, but the country-tocountry variation was large (from 36.0% to 76.9%). This variation is due to international differences in reimbursement systems rather than to angiographic indications. Our results confirm that hypersensitivity and adverse drug reactions related to contrast medium injection are less frequent after the administration of nonionic contrast medium (Table 5). These reactions were independent of the volume of contrast media injected, which was similar in both groups (Table 2). Schräder et al 25 concluded that nonionic contrast medium minimized the risk of allergic reactions in patients undergoing intervention, and Gertz et al 31 recommended that nonionic contrast medium should be used in patients undergoing cardiac angiography to minimize allergic reactions, especially in patients with known allergies. This recommendation is now also valid for patients undergoing PTCA. Study Limitations The implantation of intracoronary stents is increasing, both in Europe and worldwide. During the planning phase of the study, we anticipated an average stenting rate of 40% of patients. The results showed an 20% higher rate of stenting, and this fact might have contributed to the lower MACE rates reported than was expected. The study was planned with a 6% anticipated MACE rate. However, the lower rate of 4.3% seen at the completion of the study did not affect the study s ability to detect a difference between the contrast media groups, because the observed contrast group OR of 1.2 is well within the confidence limits specified in the study protocol. Only the 2-day MACE were evaluated by the independent end point classification committee, and this should be considered when looking at the overall results, which combine the MACE reported after 2 days with those reported after 1 month. In total, 1541 patients were enrolled, but 1411 were included in the per-protocol population. However, the fact that the intention-to-treat population results were in accordance with the per-protocol population results regarding MACE indicates that the exclusion of these patients had no influence on the results. In total, 32 centers participated in the trial, and the individual centers enrolled 2 to 112 patients. The disparity between the number of enrolled patients could have influenced the final results, but due to stratification by center, the comparison between the 2 contrast medium groups was unbiased. The use of glycoprotein IIb/IIIa receptor inhibitors was not the current practice at the enrolling centers, and it was not allowed as a preparation to intervention. Only 23 patients (1.6%) received this type of medication during or after PTCA. Conclusions No statistically significant differences were found between the iso-osmolar, nonionic contrast medium iodixanol and the low-osmolar, ionic contrast medium ioxaglate on the occurrence of MACE, either at the 2-day follow-up or during the 1-month follow-up period. In addition, the rate of abrupt closure was similar in both groups. Thus, we can conclude that in patients, including those with both stable and unstable angina, receiving iodixanol, no increase in major cardiac complications occurs when compared with those patients given ioxaglate. Furthermore, hypersensitivity and adverse drug reactions classified as certainly related to contrast medium occurred significantly less frequently in patients receiving iodixanol. Appendix Investigators France: M. Bertrand, Hôpital Cardiologique, Lille; X. Faverau, Center Médico-Chirurgical, Le Chesnay; P. Aubry, Hôpital Bichat, Paris; J.L. Guermonprez, Hôpital Broussais, Paris; M.-C. Morice, Hôpital Privé de Massy, Massy; P. Besse, Hôpital Haut Leveque, Pessac; G. Grollier, Center Hôspitalier Universitaire de Caen, Caen; P.-D. Crochet, Hôpital Laënnec, St. Herblain; A. Cribier, Hôpital
6 136 Circulation January 18, 2000 Charles Nicolle, Rouen; P. Dupouy, Hôpital Henri Mondor, Créteil; J. Boschat, Hôpital de la Cavale Blanche, Brest; K. Khalifé, Hôpital Notre Dame de Bon Secours, Metz. The Netherlands: H. Suryapranata, Ziekenhuis De Weezenlanden, Zwolle; J.J.R.M. Bonnier, Catharina Ziekenhuis, Eindhoven. Belgium: G. Heyndrickx, Onze Lieve Vrouw Ziekenhuis, Aalst; C. Hanet, Cliniques Universitaires St Luc, Bruxelles; F. Van den Branden, Middelheim Ziekenhuis, Antwerpen; M. Vrolix, St. Jan Ziekenhuis, Genk; J.H. Piessens, Universitair Ziekenhuis Gasthuisberg, Leuven; Y. Taeymans, Universitair Ziekenhuis, Gent; V. Legrand, Center Hospitalier Universitaire, Liège; J. Dekeyser, Hôpital Civil, Jumet; P. Lafontaine, Clinique St Jean, Bruxelles. Spain: C. Macaya, Hospital Universitario San Carlos, Madrid; E. Garc a-fernández, Hospital General Gregorio Marañón, Madrid; E. Esplugas and J. Mauri, Hospital de Bellvitge Princeps D Espanya, Barcelona; A. Betriu and A. Serra, Hospital Clinic I Provincial, Barcelona; A. Iñiguez, Clínica Nuestra Señora de la Concepción, Madrid; C. Morís, Hospital General de Asturias, Oviedo; T. Colman, Hospital Marqués de Valdecilla, Santander; M. Gómez-Recio, Hospital de la Princesa, Madrid. Sweden: L. Grip, Sahlgrenska Sjukhuset, Göteborg. Acknowledgments We would like to thank all the investigators for their efforts during their participation in this multicenter trial. We also wish to thank Mr Trond Haider for the statistical analysis. References 1. Esplugas E, Cequier A, Jara F, Mauri J, Soler T, Sala J, Sabate X. Risk of thrombosis during coronary angioplasty with low osmolality contrast media. Am J Cardiol. 1991;68: Lembo NJ, King SB III, Roubin GS, Black AJ, Douglas JS Jr. Effects of nonionic versus ionic contrast media on complications of percutaneous transluminal coronary angioplasty. Am J Cardiol. 1991;67: Piessens JH, Stammen F, Vrolix MC, Glazier JJ, Benit E, De Geest H, Willems JL. Effects of an ionic versus a nonionic low osmolar contrast agent on the thrombotic complications of coronary angioplasty. Cathet Cardiovasc Diagn. 1993;28: Grines CL, Schreiber TL, Savas V, Jones DE, Zidar FJ, Gangadharan V, Brodsky M, Levin R, Safian R, Puchrowicz-Ochocki S, Castellani MD, O Neill WW. A randomized trial of low osmolar ionic versus nonionic contrast media in patients with myocardial infarction or unstable angina undergoing percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1996;27: Malekianpour M, Bonan R, Lesperance J, Gosselin G, Hudon G, Doucet S, Laurier J, Duval D. Comparison of ionic and nonionic low osmolar contrast media in relation to thrombotic complications of angioplasty in patients with unstable angina. Am Heart J. 1998;135: Gasperetti CM, Feldman MD, Burwell LR, Angello DA, Haugh KH, Owen RM, Powers ER. Influence of contrast media on thrombus formation during coronary angioplasty. J Am Coll Cardiol. 1991;18: Husted SE, Kanstrup H. Thrombotic complications in coronary angioplasty: ionic versus non-ionic low-osmolar contrast media. Acta Radiol. 1998;39: Qureshi NR, den Heijer P, Crijns HJ. Percutaneous coronary angioscopic comparison of thrombus formation during percutaneous coronary angioplasty with ionic and nonionic low osmolality contrast media in unstable angina. Am J Cardiol. 1997;80: Fareed J, Walenga JM, Saravia GE, Moncada RM. Thrombogenic potential of nonionic contrast media? Radiology. 1990;174: Ing JJ, Smith DC, Bull BS. Differing mechanisms of clotting inhibition by ionic and nonionic contrast agents. Radiology. 1989;172: Chronos NA, Goodall AH, Wilson DJ, Sigwart U, Buller NP. Profound platelet degranulation is an important side effect of some types of contrast media used in interventional cardiology. Circulation. 1993;88: Corot C, Chronos N, Sabattier V. In vitro comparison of the effects of contrast media on coagulation and platelet activation. Blood Coagul Fibrinolysis. 1996;7: Brass O, Belleville J, Sabattier V, Corot C. Effect of ioxaglate an ionic low osmolar contrast medium on fibrin polymerization in vitro. Blood Coagul Fibrinolysis. 1993;4: Aguejouf O, Doutremepuich F, Azougagh Oualane F, Doutremepuich C. Thrombogenicity of ionic and nonionic contrast media tested in a laser induced rat thrombosis model. Thromb Res. 1995;77: Hardeman MR, Konijnenberg A, Sturk A, Reekers JA. Activation of platelets by low-osmolar contrast media: differential effects of ionic and nonionic agents. Radiology. 1994;192: Arora R, Khandelwal M, Gopal A. In vivo effects of nonionic and ionic contrast media on -thromboglobulin and fibrinopeptide levels. J Am Coll Cardiol. 1991;17: Albanese JR, Venditto JA, Patel GC, Ambrose JA. Effects of ionic and nonionic contrast media on in vitro and in vivo platelet activation. Am J Cardiol. 1995;76: Mamon JF, Hoppensteadt D, Fareed J, Moncada R. Biochemical evidence for a relative lack of inhibition of thrombin formation by nonionic contrast media. Radiology. 1991;179: Stormorken H, Sakariassen KS. In vitro platelet degranulation by contrast media: clinical relevance? Circulation. 1994;90: Eloy R, Corot C, Belleville J. Contrast media for angiography: physicochemical properties, pharmacokinetics and biocompatibility. Clin Mater. 1991;7: Barstad RM, Kierulf P, Sakariassen KS. Collagen induced thrombus formation at the apex of eccentric stenoses: a time course study with non-anticoagulated human blood. Thromb Haemost. 1996;75: Hathcock J, Sakariassen K, Turitto V. Tissue factor activity in rat vascular smooth muscle cells exposed to ionic and non-ionic contrast media. Thromb Haemost. 1997;78: Sakariassen KS, Barstad RM, Hamers MJ, Stormorken H. Iohexol, platelet activation, and thrombosis, I: iohexol-induced platelet secretion does not affect thrombus formation in native blood. Acta Radiol. 1998;39: Sakariassen KS, Buchmann M, Hamers MJ, Stormorken H. Iohexol, platelet activation, and thrombosis, II: iohexol-induced platelet secretion does not affect collagen-induced or tissue-factor-induced thrombus formation in blood that is anticoagulated with heparin and aspirin. Acta Radiol. 1998;39: Schräder R, Esch I, Ensslen R, Fach WA, Merle H, Scherer D, Sievert H, Spies HF, Zeplin HE. A randomized trial comparing the impact of a nonionic (iomeprol) versus an ionic (ioxaglate) low osmolar contrast medium on abrupt vessel closure and ischemic complications after coronary angioplasty. J Am Coll Cardiol. 1999;33: Lasser EC, Lyon SG, Berry CC. Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration. Radiology. 1997;203: Hill JA, Winniford M, Cohen MB, Van Fossen DB, Murphy MJ, Halpern EF, Ludbrook PA, Wexler L, Rudnick MR, Goldfarb S. Multicenter trial of ionic versus nonionic contrast media for cardiac angiography: the Iohexol Cooperative Study. Am J Cardiol. 1993;72: Barrett BJ, Parfrey PS, Vavasour HM, O Dea F, Kent G, Stone E. A comparison of nonionic, low-osmolality radiocontrast agents with ionic, high-osmolality agents during cardiac catheterization. N Engl J Med. 1992;326: Steinberg EP, Moore RD, Powe NR, Gopalan R, Davidoff AJ, Litt M, Graziano S, Brinker JA. Safety and cost effectiveness of high-osmolality as compared with low-osmolality contrast material in patients undergoing cardiac angiography. N Engl J Med. 1992;326: Hellige G, Vogel B, Tebbe U, Kreuzer H. Contrast media in cardiology: report of a randomized, double-blind multicenter comparative study of the side effects of ionic and non-ionic roentgen contrast media. Z Kardiol. 1992;81: Gertz EW, Wisneski JA, Miller R, Knudtson M, Robb J, Dragatakis L, Browne KF Jr, Vetrovec G, Smith SC Jr. Adverse reactions of low osmolality contrast media during cardiac angiography: a prospective randomized multicenter study. J Am Coll Cardiol. 1992;19:
Journal of the American College of Cardiology Vol. 33, No. 2, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 33, No. 2, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(98)00600-7 A Randomized
More informationCoronary angioplasty has undergone dramatic evolution. Randomized Trial of Contrast Media Utilization in High-Risk PTCA.
Randomized Trial of Contrast Media Utilization in High-Risk PTCA The COURT Trial Charles J. Davidson, MD; Warren K. Laskey, MD; James B. Hermiller, MD; J. Kevin Harrison, MD; William Matthai, Jr, MD; Ronald
More informationIohexol, platelet activation and thrombosis
Acta Radiologica ISSN: 0284-1851 (Print) 1600-0455 (Online) Journal homepage: https://www.tandfonline.com/loi/iard20 Iohexol, platelet activation and thrombosis Kjell S. Sakariassen, M. Buchmann, M. J.
More informationInter-regional differences and outcome in unstable angina
European Heart Journal (2000) 21, 1433 1439 doi:10.1053/euhj.1999.1983, available online at http://www.idealibrary.com on Inter-regional differences and outcome in unstable angina Analysis of the International
More informationLink between effectiveness and cost data Costing was conducted prospectively on the same patient sample as that used in the effectiveness analysis.
Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention Rabah M, Mason D, Muller D W, Hundley R, Kugelmass
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationSafety and Efficacy of Angioplasty with Intracoronary Stenting in Patients with Unstable Coronary Syndromes. Comparison with Stable Coronary Syndromes
Original Article Safety and Efficacy of Angioplasty with Intracoronary Stenting in Patients with Unstable Coronary Syndromes. Comparison with Stable Coronary Syndromes Luís C. L. Correia, José Carlos Brito,
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationInfluence of Planned Six-Month Follow-Up Angiography on Late Outcome After Percutaneous Coronary Intervention A Randomized Study
Journal of the American College of Cardiology Vol. 38, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01476-0 Influence
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationEffect of an Ionic Compared to a Non-Ionic X-Ray Contrast Agent on Platelets and Coagulation during Diagnostic Cardiac Catheterisation
Pathophysiology of Haemostasis andthrombosis Original Paper Pathophysiol Haemost Thromb 2002;32:121 126 DOI: 10.1159/000065213 Received: April 11, 2002 Accepted in revised form: May 20, 2002 Effect of
More informationA Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary Artery Stents
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02974-1
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationInterventional Cardiology METHODS
Journal of the American College of Cardiology Vol. 37, No. 6, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01207-4 Interventional
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationClopidogrel Date: 15 July 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationREBEL. Platinum Chromium Coronary Stent System. Patient Information Guide
REBEL Patient Information Guide REBEL PATIENT INFORMATION GUIDE You have recently had a REBEL bare metal stent implanted in the coronary arteries of your heart. The following information is important for
More informationPercutaneous Coronary Interventions Without On-site Cardiac Surgery
Percutaneous Coronary Interventions Without On-site Cardiac Surgery Hassan Al Zammar, MD,FESC Consultant & Interventional Cardiologist Head of Cardiology Department European Gaza Hospital Palestine European
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationJournal of the American College of Cardiology Vol. 39, No. 11, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 39, No. 11, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01856-9
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationDISRUPT CAD. Todd J. Brinton, MD Clinical Associate Professor of Medicine Adjunct Professor of Bioengineering Stanford University
DISRUPT CAD A multicenter, prospective, single-arm study of percutaneous Lithoplasty prior to stent implantation in heavily calcified coronary lesions Todd J. Brinton, MD Clinical Associate Professor of
More informationMorphological changes after percutaneous transluminal coronary angioplasty of unstable plaques
European Heart Journal (1996) 17, 1554-1559 orphological changes after percutaneous transluminal coronary angioplasty of unstable plaques Insights from serial angioscopic follow-up C. Bauters, J.-. Lablanche,
More informationSafety and Efficacy of Coronary Stent Implantation. Acute and Six Month Outcomes of 1,126 Consecutive Patients Treated in 1996 and 1997
Original Article Safety and Efficacy of Coronary Stent Implantation. Acute and Six Month Outcomes of 1,126 Consecutive Patients Treated in 1996 and 1997 Luiz Alberto Mattos, Ibraim Pinto, Alexandre Abizaid,
More informationA randomized trial of a fixed high dose vs a weight-adjusted low dose of intravenous heparin during coronary angioplasty
European Heart Journal (1997) 18, 631-635 A randomized trial of a fixed high dose vs a weight-adjusted low dose of intravenous heparin during coronary angioplasty A. Boccara, H. Benamer, J.-M. Juliard,
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationThe New England Journal of Medicine INTRAVASCULAR GAMMA RADIATION FOR IN-STENT RESTENOSIS IN SAPHENOUS-VEIN BYPASS GRAFTS
INTRAVASCULAR GAMMA RADIATION FOR IN-STENT RESTENOSIS IN SAPHENOUS-VEIN BYPASS GRAFTS RON WAKSMAN, M.D., ANDREW E. AJANI, M.D., R. LARRY WHITE, M.D., ROSANNA C. CHAN, M.D., LOWELL F. SATLER, M.D., KENNETH
More informationPrimary PCI versus thrombolytic therapy: long-term follow-up according to infarct location
Heart Online First, published on April 14, 2005 as 10.1136/hrt.2005.060152 1 Primary PCI versus thrombolytic therapy: long-term follow-up according to infarct location Short running head: Anterior infarction
More informationDiagnosis and Management of Acute Myocardial Infarction
Diagnosis and Management of Acute Myocardial Infarction Acute Myocardial Infarction (AMI) occurs as a result of prolonged myocardial ischemia Atherosclerosis leads to endothelial rupture or erosion that
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationCardiovascular Disorders Lecture 3 Coronar Artery Diseases
Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationAn Open Randomized Study Prague-5 ˆ
Next Day Discharge After Successful Primary Angioplasty for Acute ST Elevation Myocardial Infarction An Open Randomized Study Prague-5 Radovan JIRMÁR, 1 MD, Petr WIDIMSKÝ, 1 MD, Jan CAPEK, 1 MD, Ota HLINOMAZ,
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationTarget vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI
Target vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI Gamal Abdelhady, Emad Mahmoud Department of interventional
More informationTreatment of Saphenous Vein Bypass Grafts With Ultrasound Thrombolysis. A Randomized Study (ATLAS)
Treatment of Saphenous Vein Bypass Grafts With Ultrasound Thrombolysis A Randomized Study (ATLAS) Mandeep Singh, MD; Uri Rosenschein, MD; Kalon K.L. Ho, MD; Peter B. Berger, MD; Richard Kuntz, MD; David
More informationEXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)
Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) Disclosures Investigator Initiated Trial: NCT00828087. Unrestricted grant from Abbott to the Spanish Heart Foundation.
More informationARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial
ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic
More informationAngiographic and Intravascular Ultrasound Predictors of In-Stent Restenosis
1630 JACC Vol. 32, No. 6 Angiographic and Intravascular Ultrasound Predictors of In-Stent Restenosis SHUNJI KASAOKA, MD, JONATHAN M. TOBIS, MD, FACC, TATSURO AKIYAMA, MD,* BERNHARD REIMERS, MD,* CARLO
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationInfluence of Treatment Delay on Infarct Size and Clinical Outcome in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty
629 Influence of Treatment Delay on Infarct Size and Clinical Outcome in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty AYLEE L. LIEM, MD, ARNOUD W.J. VAN T HOF, MD, JAN C.A.
More informationClopidogrel and ASA after CABG for NSTEMI
Clopidogrel and ASA after CABG for NSTEMI May 17, 2007 Justin Lee Pharmacy Resident University Health Network Objectives At the end of this session, you should be able to: Explain the rationale for antiplatelet
More informationResults of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies
Intracoronary Radiation Therapy Improves the Clinical and Angiographic Outcomes of Diffuse In-Stent Restenotic Lesions Results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationC. W. Hamm, B. Cremers, H. Moellmann, S. Möbius-Winkler, U. Zeymer, M. Vrolix, S. Schneider, U. Dietz, M. Böhm, B. Scheller
Paclitaxel-Eluting PTCA-Balloon in Combination with the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease C. W. Hamm, B. Cremers, H. Moellmann,
More informationHealth technology The use of coronary stenting versus primary balloon angioplasty (PTCA) in acute myocardial infarction (AMI).
Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (Stent-PAMI) trial Cohen D J, Taira D A, Berezin R, Cox D A,
More informationPERIOPERATIVE MYOCARDIAL INFARCTION THE ANAESTHESIOLOGIST'S VIEW
PERIOPERATIVE MYOCARDIAL INFARCTION THE ANAESTHESIOLOGIST'S VIEW Bruce Biccard Perioperative Research Group, Department of Anaesthetics 18 June 2015 Disclosure Research funding received Medical Research
More informationTitle: Clinical significance of retinal emboli during diagnostic and therapeutic cardiac catheterization
Reviewer's report Title: Clinical significance of retinal emboli during diagnostic and therapeutic cardiac catheterization Version: 1 Date: 1 September 2010 Reviewer: James Wilentz Reviewer's report: All
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationStent Trials in Acute Myocardial Infarction
IAGS 1998 Proceedings Stent Trials in Acute Myocardial Infarction Alfredo Rodríguez MD, PhD Primary angioplasty in the early phase of acute myocardial infarction has been demonstrated to reduce in-hospital
More informationPeripheral and Cardiology Coder 2018
Peripheral and Cardiology Coder 2018 Cardiovascular Services and Procedures Prepared and Published By: MedLearn Publishing A Division of MedLearn Media, Inc. 445 Minnesota Street, Suite 514 St. Paul, MN
More informationStenting In Small Coronary Arteries (SISCA) Trial A Randomized Comparison Between Balloon Angioplasty and the Heparin-Coated bestent
Journal of the American College of Cardiology Vol. 38, No. 6, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01602-3 Stenting
More informationZachary I. Hodes, M.D., Ph.D., F.A.C.C.
Zachary I. Hodes, M.D., Ph.D., F.A.C.C. Disclamer: I personally have no financial relationship with any company mentioned today. The Care Group, LLC does have a contract with Cardium to participate in
More informationAcute coronary syndromes
Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.
More informationControversies in Cardiac Surgery
Controversies in Cardiac Surgery 3 years after SYNTAX : Percutaneous Coronary Intervention for Multivessel / Left main stem Coronary artery disease Pro ESC Congress 2010, 28 August 1 September Stockholm
More informationHEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM
REVIEW DATE REVIEWER'S ID HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM : DISCHARGE DATE: RECORDS FROM: Hospitalization ER Please check all that may apply: Myocardial Infarction Pages 2, 3,
More informationEarly Exercise After Coronary Stenting Is Safe
Journal of the American College of Cardiology Vol. 42, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)01122-7
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationJournal of the American College of Cardiology Vol. 38, No. 3, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 38, No. 3, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01423-1 Effect
More informationAre Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of
More informationHon-Kan Yip, MD; Chiung-Jen Wu, MD; Morgan Fu, MD; Kuo-Ho Yeh, MD; Teng-Hung Yu, MD; Wei-Chin Hung, MD; and Mien-Cheng Chen, MD
Clinical Features and Outcome of Patients With Direct Percutaneous Coronary Intervention for Acute Myocardial Infarction Resulting From Left Circumflex Artery Occlusion* Hon-Kan Yip, MD; Chiung-Jen Wu,
More informationFFR vs. icecg in Coronary Bifurcations (FIESTA) - preliminary results. Dobrin Vassilev MD, PhD National Heart Hospital Sofia, Bulgaria
FFR vs. icecg in Coronary Bifurcations (FIESTA) - preliminary results Dobrin Vassilev MD, PhD National Heart Hospital Sofia, Bulgaria I would like to express my personal gratitude to Dr. BK Koo for opening
More informationStent Thrombosis in Bifurcation Stenting
Summit TCT Asia Pacific 2009 Stent Thrombosis in Bifurcation Stenting Associate Professor Tan Huay Cheem MBBS, M Med(Int Med), MRCP, FRCP(UK), FAMS, FACC, FSCAI Director, National University Heart Centre,
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationWOEST ESC, Hotline III, Munchen, August 28th, 2012
ESC, Hotline III, Munchen, August 28th, 2012 The WOEST Trial: First randomised trial comparing two regimens with and without aspirin in patients on oral anticoagulant therapy undergoing coronary stenting
More informationAcute Myocardial Infarction. Willis E. Godin D.O., FACC
Acute Myocardial Infarction Willis E. Godin D.O., FACC Acute Myocardial Infarction Definition: Decreased delivery of oxygen and nutrients to the myocardium Myocardial tissue necrosis causing irreparable
More informationbivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company
bivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company 06 August 2010 The Scottish Medicines Consortium (SMC) has completed its
More informationAcute Myocardial Infarction
Acute Myocardial Infarction Hafeza Shaikh, DO, FACC, RPVI Lourdes Cardiology Services Asst.Program Director, Cardiology Fellowship Associate Professor, ROWAN-SOM Acute Myocardial Infarction Definition:
More information- Mohammad Sinnokrot. -Ensherah Mokheemer. - Malik Al-Zohlof. 1 P a g e
-1 - Mohammad Sinnokrot -Ensherah Mokheemer - Malik Al-Zohlof 1 P a g e Introduction Two of the most important problems you will face as a doctor are coagulation and bleeding, normally they are in balance,
More informationContemporary Percutaneous Coronary Intervention Versus Balloon Angioplasty for Multivessel Coronary Artery Disease
Contemporary Percutaneous Coronary Intervention Versus Balloon Angioplasty for Multivessel Coronary Artery Disease A Comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the
More informationIschaemic heart disease. IInd Chair and Clinic of Cardiology
Ischaemic heart disease IInd Chair and Clinic of Cardiology Definition Syndrome due to chronic insufficient oxygen supply to myocardial cells Nomenclature: ischaemic heart disease (IHD), coronary artery
More informationCatheter Interventions for Kawasaki Disease: Current Concepts and Future Directions
REVIEW DOI 10.4070/kcj.2011.41.2.53 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright 2011 The Korean Society of Cardiology Open Access Catheter Interventions for Kawasaki Disease: Current Concepts
More informationTreatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement
Treatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement Pharmaceutical Care Project Outcomes Literature Evaluation
More informationFFR in Multivessel Disease
FFR in Multivessel Disease April, 26 2013 Coronary Physiology in the Catheterization Laboratory Location: European Heart House, Nice, France Pim A.L. Tonino, MD, PhD Hartcentrum, Eindhoven, the Netherlands
More informationClinical Investigations
Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen
More informationModeling and Risk Prediction in the Current Era of Interventional Cardiology
Modeling and Risk Prediction in the Current Era of Interventional Cardiology A Report From the National Heart, Lung, and Blood Institute Dynamic Registry David R. Holmes, MD; Faith Selzer, PhD; Janet M.
More informationCoronary Plaque Sealing: The DEFER Study and more...
Coronary Plaque Sealing: The DEFER Study and more... How Waiting Can Be Beneficial in Stable Coronary Artery Disease Patients ESC, Stockholm, 2005 M. Romanens, 21.09.2005 at www.kardiolab.ch DEFER Study:
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More informationVersion 4.4. Institutional Outcomes Report 2014Q3. National Outcomes Report Aggregation Date: Jan 12, :59:59 PM
Version 4.4 Institutional Outcomes Report 2014Q3 National Outcomes Report 999997 Aggregation Date: Jan 12, 2015 11:59:59 PM Publish Date: Jan 29, 2015 If User desires to publish or otherwise distribute
More informationAlex versus Xience Registry Preliminary report
Interventional Cardiology Network Alex versus Xience Preliminary report Mariusz Gąsior 1,2, Marek Gierlotka 1, Lech Poloński 1,2 1 3rd Department of Cardiology, Medical University of Silesia Centre tor
More informationJournal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationThe Clinical Evaluation of the Medtronic AVE Driver Coronary Stent System
The Clinical Evaluation of the Medtronic AVE Driver Coronary Stent System A prospective, multicenter, non randomized study to evaluate the safety and efficacy of the Medtronic AVE Driver Coronary Stent
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationUPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME. DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18
UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18 INTRODUCTION The clinical entities that comprise acute coronary syndromes (ACS)-ST-segment
More information(For items 1-12, each question specifies mark one or mark all that apply.)
Form 121 - Report of Cardiovascular Outcome Ver. 9.2 COMMENTS -Affix label here- Member ID: - - To be completed by Physician Adjudicator Date Completed: - - (M/D/Y) Adjudicator Code: - Central Case No.:
More informationJournal of the American College of Cardiology Vol. 34, No. 7, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 34, No. 7, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00443-X CLINICAL
More informationAcute coronary syndrome (ACS) is an
OVERVIEW OF MEDICAL MANAGEMENT OF ACUTE CORONARY SYNDROMES Robert B. Parker, PharmD * Acute coronary syndrome (ACS) is an umbrella term used to describe any group of symptoms of acute myocardial ischemia
More informationLong term outcome and cost-evectiveness of stenting versus balloon angioplasty for acute myocardial infarction
Heart 2001;85:667 671 667 Department of Cardiology, Isala Klinieken, Hospital de Weezenlanden, Groot Wezenland 20, 8011 JW Zwolle, Netherlands H Suryapranata J P Ottervanger E Nibbering AWJvan thof J C
More informationDiagnostic & Therapeutic Cardiac Catheterization Coder 2017
Diagnostic & Therapeutic Cardiac Catheterization Coder 2017 Including peripheral and cardiovascular services and procedures Prepared and Published By: MedLearn Publishing A Division of Panacea Healthcare
More informationΣεμινάριο Ομάδων Εργασίας Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική
ΕΛΛΗΝΙΚΗΚΑΡΔΙΟΛΟΓΙΚΗΕΤΑΙΡΕΙΑ Σεμινάριο Ομάδων Εργασίας 2011 Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική GUIDELINES ON MYOCARDIAL
More information